Directed Evolution of p53 Variants with Altered DNA-binding Specificities by In Vitro Compartmentalization

Journal of Molecular Biology

Volumn 371, Issue 5, 2007, Pages 1238-1248

  Fen, Chen Xue ^a   Coomber, David W ^a   Lane, David P ^a   Ghadessy, Farid J ^a  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

DNA binding; in vitro compartmentalization; mutant; p53; response element

Indexed keywords

PROLINE; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL COMPARTMENTALIZATION; CELL CYCLE ARREST; CELL FATE; CONTROLLED STUDY; DNA BINDING; DNA RESPONSIVE ELEMENT; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN VARIANT; REPORTER GENE; TRANSACTIVATION; TRANSCRIPTION INITIATION; UPREGULATION;

EID: 34547661589     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.05.099     Document Type: Article

References (59)

1. Beroud C., and Soussi T. The UMD-p53 database: new mutations and analysis tools. Hum. Mutat. 21 (2003) 176-181
2. Vogelstein B., Lane D.P., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
3. Polyak K., Xia Y., Zweier J.L., Kinzler K.W., and Vogelstein B. A model for p53-induced apoptosis. Nature 389 (1997) 300-305
4. Yu J., Zhang L., Hwang P.M., Rago C., Kinzler K.W., and Vogelstein B. Identification and classification of p53-regulated genes. Proc. Natl Acad. Sci. USA 96 (1999) 14517-14522
5. Marchenko N.D., Zaika A., and Moll U.M. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J. Biol. Chem. 275 (2000) 16202-16212
6. Mihara M., Erster S., Zaika A., Petrenko O., Chittenden T., Pancoska P., and Moll U.M. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 11 (2003) 577-590
7. Funk W.D., Pak D.T., Karas R.H., Wright W.E., and Shay J.W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12 (1992) 2866-2871
8. el Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., and Vogelstein B. Definition of a consensus binding site for p53. Nature Genet. 1 (1992) 45-49
9. Tomso D.J., Inga A., Menendez D., Pittman G.S., Campbell M.R., Storici F., et al. Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. Proc. Natl Acad. Sci. USA 102 (2005) 6431-6436
10. Resnick M.A., Tomso D., Inga A., Menendez D., and Bell D. Functional diversity in the gene network controlled by the master regulator p53 in humans. Cell Cycle 4 (2005) 1026-1029
11. Laptenko O., and Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death. Differ. 13 (2006) 951-961
12. Friedlander P., Haupt Y., Prives C., and Oren M. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol. 16 (1996) 4961-4971
13. Qian H., Wang T., Naumovski L., Lopez C.D., and Brachmann R.K. Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. Oncogene 21 (2002) 7901-7911
14. Weinberg R.L., Veprintsev D.B., Bycroft M., and Fersht A.R. Comparative binding of p53 to its promoter and DNA recognition elements. J. Mol. Biol. 348 (2005) 589-596
15. Hupp T.R., Lane D.P., and Ball K.L. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem. J. 352 (2000) 1-17
16. Bullock A.N., and Fersht A.R. Rescuing the function of mutant p53. Nature Rev. Cancer 1 (2001) 68-76
17. Woods Y.L., and Lane D.P. Exploiting the p53 pathway for cancer diagnosis and therapy. Hematol. J. 4 (2003) 233-247
18. Hainaut P., Hernandez T., Robinson A., Rodriguez-Tome P., Flores T., Hollstein M., et al. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucl. Acids Res. 26 (1998) 205-213
19. Wong K.B., DeDecker B.S., Freund S.M., Proctor M.R., Bycroft M., and Fersht A.R. Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc. Natl Acad. Sci. USA 96 (1999) 8438-8442
20. Brachmann R.K., Yu K., Eby Y., Pavletich N.P., and Boeke J.D. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J. 17 (1998) 1847-1859
21. Wieczorek A.M., Waterman J.L., Waterman M.J., and Halazonetis T.D. Structure-based rescue of common tumor-derived p53 mutants. Nature Med. 2 (1996) 1143-1146
22. Campomenosi P., Monti P., Aprile A., Abbondandolo A., Frebourg T., Gold B., et al. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 20 (2001) 3573-3579
23. Ludwig R.L., Bates S., and Vousden K.H. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell. Biol. 16 (1996) 4952-4960
24. Rowan S., Ludwig R.L., Haupt Y., Bates S., Lu X., Oren M., and Vousden K.H. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J. 15 (1996) 827-838
25. Ryan K.M., and Vousden K.H. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol. Cell. Biol. 18 (1998) 3692-3698
26. Freeman J., Schmidt S., Scharer E., and Iggo R. Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein. EMBO J. 13 (1994) 5393-5400
27. Thukral S.K., Lu Y., Blain G.C., Harvey T.S., and Jacobsen V.L. Discrimination of DNA binding sites by mutant p53 proteins. Mol. Cell. Biol. 15 (1995) 5196-5202
28. Saller E., Tom E., Brunori M., Otter M., Estreicher A., Mack D.H., and Iggo R. Increased apoptosis induction by 121F mutant p53. EMBO J. 18 (1999) 4424-4437
29. Kato S., Han S.Y., Liu W., Otsuka K., Shibata H., Kanamaru R., and Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl Acad. Sci. USA 100 (2003) 8424-8429
30. Tawfik D.S., and Griffiths A.D. Man-made cell-like compartments for molecular evolution. Nature Biotechnol. 16 (1998) 652-656
31. Cohen H.M., Tawfik D.S., and Griffiths A.D. Altering the sequence specificity of HaeIII methyltransferase by directed evolution using in vitro compartmentalization. Protein Eng. Des. Sel. 17 (2004) 3-11
32. Ghadessy F.J., and Holliger P. Compartmentalized self-replication: a novel method for the directed evolution of polymerases and other enzymes. Methods Mol. Biol. 352 (2007) 237-248
33. Ghadessy F.J., Ramsay N., Boudsocq F., Loakes D., Brown A., Iwai S., et al. Generic expansion of the substrate spectrum of a DNA polymerase by directed evolution. Nature Biotechnol. 22 (2004) 755-759
34. Sepp A., and Choo Y. Cell-free selection of zinc finger DNA-binding proteins using in vitro compartmentalization. J. Mol. Biol. 354 (2005) 212-219
35. el Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
36. Yu J., Zhang L., Hwang P.M., Kinzler K.W., and Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7 (2001) 673-682
37. Nakano K., and Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7 (2001) 683-694
38. Zupnick A., and Prives C. Mutational analysis of the p53 core domain L1 loop. J. Biol. Chem. 281 (2006) 20464-20473
39. Zhu J., Jiang J., Zhou W., Zhu K., and Chen X. Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity. Oncogene 18 (1999) 2149-2155
40. Edwards S.J., Hananeia L., Eccles M.R., Zhang Y.F., and Braithwaite A.W. The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions. Oncogene 22 (2003) 4517-4523
41. Kakudo Y., Shibata H., Otsuka K., Kato S., and Ishioka C. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res. 65 (2005) 2108-2114
42. Inga A., Monti P., Fronza G., Darden T., and Resnick M.A. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay. Oncogene 20 (2001) 501-513
43. Resnick M.A., and Inga A. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc. Natl Acad. Sci. USA 100 (2003) 9934-9939
44. Cho Y., Gorina S., Jeffrey P.D., and Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265 (1994) 346-355
45. Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L., Haran T.E., and Shakked Z. Structural basis of DNA recognition by p53 tetramers. Mol. Cell 22 (2006) 741-753
46. Nikolova P.V., Wong K.B., DeDecker B., Henckel J., and Fersht A.R. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J. 19 (2000) 370-378
47. Klein C., Planker E., Diercks T., Kessler H., Kunkele K.P., Lang K., et al. NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA. J. Biol. Chem. 276 (2001) 49020-49027
48. Zhao K., Chai X., Johnston K., Clements A., and Marmorstein R. Crystal structure of the mouse p53 core DNA-binding domain at 2.7 Å resolution. J. Biol. Chem. 276 (2001) 12120-12127
49. Rippin T.M., Freund S.M., Veprintsev D.B., and Fersht A.R. Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding. J. Mol. Biol. 319 (2002) 351-358
50. Walker K.K., and Levine A.J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl Acad. Sci. USA 93 (1996) 15335-15340
51. Venot C., Maratrat M., Dureuil C., Conseiller E., Bracco L., and Debussche L. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 17 (1998) 4668-4679
52. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., and Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19 (2002) 607-614
53. Hoshida Y., Hongyo T., Xu J.X., Sasaki T., Tomita Y., Nomura T., and Aozasa K. TP53 gene mutation, an unfavorable prognostic factor for malignant lymphomas in autoimmune diseases. Oncology 69 (2005) 175-183
54. Seidl H., Kreimer-Erlacher H., Back B., Soyer H.P., Hofler G., Kerl H., and Wolf P. Ultraviolet exposure as the main initiator of p53 mutations in basal cell carcinomas from psoralen and ultraviolet A-treated patients with psoriasis. J. Invest. Dermatol. 117 (2001) 365-370
55. Zaccolo M., and Gherardi E. The effect of high-frequency random mutagenesis on in vitro protein evolution: a study on TEM-1 beta-lactamase. J. Mol. Biol. 285 (1999) 775-783
56. Lu X., Burbidge S.A., Griffin S., and Smith H.M. Discordance between accumulated p53 protein level and its transcriptional activity in response to u.v. radiation. Oncogene 13 (1996) 413-418
57. Jagelska E., Brazda V., Pospisilova S., Vojtesek B., and Palecek E. New ELISA technique for analysis of p53 protein/DNA binding properties. J. Immunol. Methods 267 (2002) 227-235
58. Yoo Y.A., Kim M.J., Park J.K., Chung Y.M., Lee J.H., Chi S.G., et al. Mitochondrial ribosomal protein L41 suppresses cell growth in association with p53 and p27Kip1. Mol. Cell. Biol. 25 (2005) 6603-6616
59. Hupp T.R., Meek D.W., Midgley C.A., and Lane D.P. Regulation of the specific DNA binding function of p53. Cell 71 (1992) 875-886